Related Experiment Video
Updated: Jun 5, 2026
23:33
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
The pharmaceutical pipeline for atrial fibrillation
Pasquale Santangeli1, Luigi Di Biase, Gemma Pelargonio
1Texas Cardiac Arrhythmia Institute, St. David's Medical Center, Austin, TX 78705, USA.
Annals of Medicine
|December 21, 2010
Summary
New antiarrhythmic drugs for atrial fibrillation (AF) aim to improve safety and efficacy. Novel agents like dronedarone and vernakalant show promise in managing AF, with ongoing research into traditional drug repurposing.
Area of Science:
- Cardiology and Pharmacology
- Focus on cardiovascular drug development and atrial fibrillation management.
Background:
- Atrial fibrillation (AF) significantly increases morbidity and mortality.
- Current antiarrhythmic drug therapy faces challenges with toxicity and proarrhythmia.
- Development of new drugs prioritizes multichannel blocking, atrial selectivity, and reduced adverse events.
Purpose of the Study:
- To review recent advances in antiarrhythmic therapy for atrial fibrillation (AF).
- To discuss the clinical utility of novel antifibrillatory agents.
- To highlight strategies for safer and more effective AF management.
Main Methods:
- Review of modern antiarrhythmic drug development strategies.
- Analysis of dronedarone's characteristics and clinical outcomes.
- Evaluation of atrial-selective agents like vernakalant.
- Exploration of evidence supporting traditional non-antiarrhythmic drugs for AF.
Main Results:
- Dronedarone, an amiodarone analog, reduces AF-related hospitalizations with less systemic toxicity.
- Vernakalant demonstrates efficacy in acute AF conversion with a low risk of proarrhythmia.
- Emerging evidence supports the use of renin-angiotensin system blockers, statins, and omega-3 fatty acids as antiarrhythmic therapies.
Conclusions:
- Modern antiarrhythmic drug development focuses on improved safety profiles and targeted efficacy.
- Novel agents and repurposed traditional drugs offer promising therapeutic avenues for atrial fibrillation.
- Continued research is essential to optimize AF management and reduce patient burden.
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:12Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:25Dysrhythmias VI: Management of Dysrhythmias
Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...